Considering allogeneic stem cell transplant using digital patient stories and values tools
Feasibility and Preliminary Efficacy of a Digital Story Intervention to Facilitate Decision-Making in Patients With Myeloid Cancers Considering Allogeneic Hematopoietic Cell Transplantation
This program will test whether digital patient stories plus values-clarification exercises help adults with myeloid cancers who are deciding about allogeneic hematopoietic cell transplantation make choices that fit their goals.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | University of Rochester Academic / other |
| Locations | 1 site (Rochester, New York) |
| Trial ID | NCT07263074 on ClinicalTrials.gov |
What this trial studies
This is a two-arm pilot randomized trial comparing a digital storytelling and values-clarification intervention (CHORDS) to usual care for patients with myeloid malignancies who are considering allogeneic hematopoietic cell transplantation. The CHORDS intervention combines real-life digital videos from patients and caregivers who underwent transplant consultation with an interactive workbook and best-worst scaling exercises to help users reflect on their emotions and priorities. Participants are randomized to receive CHORDS or usual care and outcomes focus on feasibility and preliminary signals of improved decision quality and emotional awareness. The study is conducted at the University of Rochester with adult English-speaking patients and optional caregiver involvement.
Who should consider this trial
Good fit: Adults over 21 with a myeloid malignancy who are being considered for allogeneic hematopoietic cell transplantation, able to consent and speak English, are ideal candidates.
Not a fit: Patients who are not considering alloHCT, cannot speak English, or have psychiatric or cognitive conditions that preclude informed consent are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, the intervention could help patients clarify their values, reduce decisional conflict, and make treatment decisions that better match their goals and expectations.
How similar studies have performed: Decision aids and values-clarification tools have shown benefit in other settings, but using digital peer stories specifically to aid alloHCT decision-making is a novel, pilot approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Patients Inclusion criteria: 1. Age \>21 years old 2. Diagnosis of myeloid cancer (AML, MDS, myelofibrosis, CML, or MDS/MPN) 3. Being considered for alloHCT 4. Able to provide informed consent 5. Able to speak English. The reason for this is because the digital stories have been created in the English language and their multimedia form cannot easily be translated. Exclusion criteria 1) Patients with psychiatric or cognitive conditions which the hematologist believes prohibits informed consent or compliance with study procedures Caregivers Inclusion criteria: 1. Age \>18 years old 2. Selected by the patient when asked if there is a "family member, partner, friend or caregiver with whom you discuss or who can be helpful in health-related matters." 3. Caregiver may be paid/professional or informal caregiver 4. Able to provide informed consent 5. Able to speak English Exclusion Criteria: 1\) None Hematologists Inclusion criteria: 1\) Hematologists of the patients who agree to enroll on the study who are part of Wilmot Cancer Institute. Exclusion criteria 1\) None
Where this trial is running
Rochester, New York
- University of Rochester — Rochester, New York, United States (Recruiting)
Study contacts
- Study coordinator: Rachel Rodenbach, MD, MS
- Email: rachel_rodenbach@urmc.rochester.edu
- Phone: 585-275-5830
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.